Reclast (Zoledronic Acid) vs Prolia (Denosumab): Long-Term Durability of Response

What the Major Trials Actually Show About Fracture Reduction

Both drugs reduce vertebral fractures by roughly two-thirds compared with placebo, but the trial populations, secondary endpoints, and follow-up designs differ in ways that matter clinically.

HORIZON-PFT: The Zoledronic Acid Evidence Base

The HORIZON Key Fracture Trial randomized 7,765 postmenopausal women with osteoporosis to zoledronic acid 5 mg IV once yearly or placebo for 3 years. Vertebral fracture risk dropped by 70% (3.3% vs 10.9%; P<0.001). Hip fracture risk fell by 41% and non-vertebral fracture risk by 25%, both statistically significant. The trial also enrolled a hip-fracture subgroup and showed a 28% reduction in subsequent clinical fractures in that population, making zoledronic acid one of the few agents with prospective data in the acute post-hip-fracture setting [1].

The drug binds permanently to hydroxyapatite in bone matrix. That permanent binding is why antiresorptive activity persists long after circulating drug levels fall to zero, a pharmacological trait no RANKL inhibitor shares.

FREEDOM: The Denosumab Evidence Base

The FREEDOM trial randomized 7,808 postmenopausal women aged 60 to 90 with a T-score between -2.5 and -4.0 to denosumab 60 mg subcutaneously every 6 months or placebo for 3 years. Vertebral fracture risk fell by 68% (2.3% vs 7.2%; P<0.001), hip fracture by 40%, and non-vertebral fracture by 20% [2].

Lumbar spine BMD increased by 9.2% and femoral neck BMD by 6.0% at 36 months, gains larger in absolute terms than those seen with zoledronic acid in HORIZON-PFT. The mechanism explains this: denosumab fully suppresses RANKL-driven osteoclast activity for the entire dosing interval, producing deeper and faster BMD accrual [2].

Head-to-Head Comparison: DECIDE and Related Data

No single large randomized trial has directly compared the two agents on fracture outcomes. The DECIDE trial (N=504) compared BMD changes over 12 months and found denosumab produced significantly greater gains at the total hip (3.5% vs 2.6%; P<0.0001) and femoral neck compared with zoledronic acid, though fracture endpoints were not powered. DECIDE confirmed denosumab's BMD superiority at the hip over one year but did not resolve which agent produces better long-term fracture outcomes [3].

Long-Term Durability: What Happens After Years of Treatment

This is where the two drugs diverge most sharply, and it is the question most relevant to patients planning therapy beyond 3 to 5 years.

Zoledronic Acid: The Case for a Treatment Holiday

The HORIZON-PFT extension followed patients who completed 3 years of zoledronic acid and then were re-randomized to 3 more years of active drug or placebo. After 6 total years of zoledronic acid, lumbar spine BMD was 3.2% higher than baseline, and the group that stopped after year 3 retained most of their BMD advantage compared with the placebo-only group. The 6-year HORIZON extension found no statistically significant difference in morphometric vertebral fracture rates between the 3-year and 6-year groups in the low-risk subgroup, suggesting that after 3 annual infusions, a drug holiday of at least 3 years is reasonable for patients at lower subsequent fracture risk [4].

That durability reflects the drug's skeletal binding kinetics. Zoledronic acid has an estimated terminal half-life in bone exceeding 10 years. Bone remodeling markers (serum CTX, P1NP) remain suppressed for 12 to 24 months after the last infusion, providing a biological buffer during any treatment gap [4].

Denosumab: Gains During Treatment, Risk After Stopping

The FREEDOM extension enrolled patients through 10 years of continuous denosumab. BMD at the lumbar spine rose by 21.7% from the original baseline, and femoral neck BMD rose by 9.2%, the largest sustained gains documented for any approved antiresorptive in a phase 3 program. Fracture incidence in the long-term cohort remained low and consistent, roughly 1 to 2% annually for new vertebral fractures [5].

The problem surfaces the moment denosumab stops. RANKL suppression reverses within weeks of a missed dose. Bone turnover markers rebound above pretreatment levels within 3 to 6 months, and BMD returns toward baseline within 12 months. More seriously, multiple observational studies have documented a cluster of multiple spontaneous vertebral fractures occurring 7 to 24 months after discontinuation. A systematic review of post-denosumab discontinuation data reported multiple vertebral fractures in up to 7.1% of patients who stopped without bridging antiresorptive therapy [6].

The FDA added language to the Prolia prescribing information in 2022 emphasizing this risk and recommending transition to an alternative antiresorptive after stopping denosumab [7].

The Practical Durability Verdict

For patients who can stay on therapy indefinitely, denosumab's 10-year BMD data are impressive. For patients who may need to stop, because of cost, side effects, surgery, or personal choice, zoledronic acid's residual skeletal protection after stopping is a meaningful safety advantage. Durability is not just about what happens during treatment. It also includes what happens when treatment ends.

Safety Profiles Over Time: Where the Two Drugs Differ

Both agents carry class-level risks related to profound antiresorptive activity, but the specific risk profiles differ.

Osteonecrosis of the Jaw and Atypical Femur Fractures

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) occur with both drugs. Risk rises with treatment duration. For zoledronic acid, AFF risk after more than 3 years of continuous therapy is estimated at roughly 1 per 1,000 patient-years based on observational data; for denosumab, risk appears similar or slightly lower per year of therapy but does not carry a residual risk after stopping, because the drug clears [8].

ONJ incidence in osteoporosis patients (as opposed to oncology patients receiving much higher doses) remains low for both agents: fewer than 1 in 10,000 patient-years in most registry analyses [8].

Renal Safety

Zoledronic acid requires adequate hydration before infusion and is contraindicated when eGFR falls below 35 mL/min/1.73m². Acute-phase reactions (fever, myalgia, arthralgia within 72 hours of infusion) occur in roughly 32% of patients after the first dose but drop to under 7% after subsequent infusions [1].

Denosumab has no renal dose restriction, making it the preferred option in chronic kidney disease stages 3 to 4. Hypocalcemia is the principal laboratory concern, especially in patients with vitamin D deficiency or advanced renal impairment, clinicians should confirm 25-OH vitamin D above 30 ng/mL before initiating denosumab [2].

Infection Risk

Denosumab's mechanism involves RANKL blockade; RANKL also plays a role in immune signaling. The FREEDOM trial documented a small but statistically significant increase in non-serious skin infections (cellulitis: 0.3% vs 0.1%; P=0.002) in the denosumab arm [2]. Serious infection rates were not significantly elevated, but the signal warrants monitoring in immunocompromised patients.

Switching Between Zoledronic Acid and Denosumab

Switching from Zoledronic Acid to Denosumab

This transition is clinically straightforward. Because zoledronic acid remains embedded in bone matrix, the antiresorptive floor is maintained while denosumab is initiated. BMD typically continues to rise after the switch. Timing is flexible, denosumab can begin at the next scheduled annual infusion date or earlier if clinical circumstances require [9].

Switching from Denosumab to Zoledronic Acid: The Critical Window

This direction requires precise timing and is the scenario most clinicians get wrong. The goal is to administer zoledronic acid before RANKL-mediated rebound accelerates, ideally within 6 months of the last denosumab dose, which corresponds to the point when bone turnover markers begin rising sharply.

The 2022 American Society for Bone and Mineral Research (ASBMR) task force report on denosumab discontinuation recommends administering zoledronic acid approximately 6 months after the last denosumab injection, regardless of whether a prior bisphosphonate was used [10]. A single infusion of zoledronic acid at that 6-month mark appears to blunt, though not fully eliminate, the rebound BMD loss.

Waiting longer than 6 months substantially increases rebound risk. Patients who miss the transition window, either because of unclear follow-up or patient preference, may require re-treatment with denosumab rather than a prolonged gap [10].

The clinical framework for sequencing decisions looks like this:

If a patient is switching OFF denosumab:

1. Check P1NP or CTX at month 5 post-last-injection.
2. If bone turnover markers are rising, schedule zoledronic acid infusion at month 6 (not later).
3. If eGFR is <35 mL/min/1.73m², consult nephrology; oral bisphosphonate alternatives (alendronate 70 mg weekly for 8 to 12 weeks) may serve as a bridge.
4. Recheck BMD and bone turnover markers 12 months post-zoledronic acid to confirm response.

If a patient is switching TO denosumab from zoledronic acid:

1. No urgency. Initiate denosumab at the next annual infusion window.
2. Document the switch explicitly so future providers do not inadvertently discontinue denosumab without a bridge plan.

Dosing, Administration, and Patient Adherence

Zoledronic Acid Dosing

Zoledronic acid 5 mg is delivered as a single 15-minute IV infusion once yearly for osteoporosis treatment (3 years for prevention). The once-yearly schedule eliminates daily or weekly pill burden. Adherence at 12 months in real-world studies exceeds 70%, substantially higher than oral bisphosphonates, which show 12-month adherence rates of 40 to 60% in most registry analyses [11].

Pre-infusion hydration with 500 mL of normal saline reduces acute-phase reaction severity. Patients should be counseled to take acetaminophen 650 to 1,000 mg before the infusion and every 6 hours for 24 to 48 hours afterward to manage post-infusion flu-like symptoms.

Denosumab Dosing

Denosumab 60 mg is administered subcutaneously every 6 months, typically in a clinic setting, though some practices train patients or caregivers for home administration. The biannual schedule is convenient but creates an adherence cliff: a delay of even 4 to 8 weeks beyond the scheduled injection date begins allowing bone turnover marker rebound. A 2019 real-world analysis in Osteoporosis International found that 20% of denosumab patients in clinical practice had at least one injection delayed by more than 8 weeks, placing them at elevated rebound risk [12].

Automated recall systems, patient reminder apps, and pharmacy-based injection services significantly reduce delay rates. Any practice prescribing denosumab should have a structured recall protocol in place before initiating therapy.

Who Should Get Which Drug? A Clinician-Facing Decision Guide

Favor Zoledronic Acid When:

• The patient may need to stop therapy within 3 to 5 years (surgery, malignancy, personal choice).
• Prior oral bisphosphonate failure or intolerance is documented.
• The patient has CKD with eGFR 35 to 60 mL/min/1.73m² (zoledronic acid is still usable; denosumab preferred below 35).
• The patient recently sustained a hip fracture and benefits from the HORIZON hip-fracture cohort data.
• Cost or insurance access for twice-yearly injections is a barrier.

Favor Denosumab When:

• eGFR is <35 mL/min/1.73m² and the patient cannot tolerate IV bisphosphonates.
• Maximal BMD gain is the primary goal (e.g., very high fracture risk, T-score below -3.5).
• The patient has a strong recall system and commits to lifelong therapy or a planned bisphosphonate transition.
• Prior IV bisphosphonate caused significant acute-phase reactions not manageable with acetaminophen.
• The prescriber and patient have explicitly planned the stop strategy before starting.

The American Association of Clinical Endocrinology 2020 guidelines note that denosumab is a first-line option for patients unable to take oral bisphosphonates but emphasize that "transition therapy after denosumab discontinuation is mandatory to prevent rebound bone loss" [13].

The Endocrine Society 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women recommends considering a drug holiday after 3 to 5 years of bisphosphonate therapy in patients at moderate risk, but explicitly advises against unplanned denosumab discontinuation [14].

Cost and Access Considerations

Zoledronic acid is available as a generic in the United States. Annual infusion cost ranges from roughly $150, $400 in generic form, plus administration fees. Brand Reclast costs considerably more, but most insurers and Medicare Part B cover the generic formulation with minimal out-of-pocket burden.

Prolia (denosumab) remains under patent through the mid-2020s in the United States, with biosimilar approvals pending. List price is approximately $1,400 per 6-month injection. Medicare Part B covers it under the medical benefit at the provider's office. Copay assistance programs are available for commercially insured patients earning above the threshold for patient assistance programs. A biosimilar, Jubbonti (denosumab-bbdz), received FDA approval in March 2024, with additional biosimilars in the pipeline that may reduce cost substantially [15].

Key Takeaways for Long-Term Management

Zoledronic acid and denosumab are both highly effective at reducing vertebral and hip fractures, the head-to-head fracture data do not clearly favor one over the other. The clinical difference comes down to what happens at the end of treatment.

Zoledronic acid's bone-binding pharmacology provides a residual antifracture buffer that makes treatment pauses safer. Denosumab's RANKL blockade produces greater BMD gains during therapy but requires an explicit exit strategy every time a prescriber considers stopping it.

Patients switching from denosumab to zoledronic acid should receive the infusion at exactly 6 months after the last denosumab injection. Waiting longer increases multiple vertebral fracture risk in a measurable, documented way. Every denosumab patient needs a documented stop plan before the first dose is administered.